BSK-01 / Kiromic - LARVOL DELTA

Kiromic BioPharma, Now Clinical Stage, Reports Significant Progression Free Survival Benefit in Metastatic Pancreatic Cancer Patient Treated with KiroVax/BSK01, Company’s Phase 1 Cell Therapy Cancer Vaccine Candidate for Solid Tumors (Businesswire) - P1, N=NA; "Kiromic BioPharma, Inc...announces the results of a published pilot Phase 1 clinical trial that showed KiroVax/BSK01, Kiromic’s cell therapy cancer vaccine candidate, in combination with chemotherapy, demonstrated a significant progression free survival (PFS) benefit in one of the patients with metastatic pancreatic cancer who participated in the trial. The results from the pilot Phase 1 clinical trial demonstrated PFS of 7 months after treatment with KiroVAX/BSK01 and chemotherapy versus PFS of 3.9 months with second line chemotherapy...illustrate stable disease in a pancreatic cancer patient with lung metastasis which initially increased in size to 270mm2 and then subsequently stabilized at 100mm2 after three months of treatment with KiroVax/BSK01 in combination with chemotherapy, resulting in a progression free survival (PFS) of 7 months."

P1 data • Gastrointestinal Cancer • Oncology • Pancreatic Cancer

Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies (clinicaltrials.gov) - P1/2; N=3; Terminated; Sponsor: Kiromic, Inc.; N=17 ➔ 3; Active, not recruiting ➔ Terminated; Sponsor decision to terminate study due to poor accrual

Clinical • Enrollment change • Trial termination

Consolidation Therapy in Patients With Hematologic Malignancies (clinicaltrials.gov) - P1/2; N=0; Withdrawn; Sponsor: Kiromic, Inc.; N=17 ➔ 0; Active, not recruiting ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal

Consolidation Therapy in Patients With Hematologic Malignancies (clinicaltrials.gov) - P1/2; N=17; Active, not recruiting; Sponsor: Kiromic, Inc.; Trial completion date: Jan 2019 ➔ Oct 2020; Trial primary completion date: Oct 2018 ➔ Oct 2020

Clinical • Trial completion date • Trial primary completion date

Cyclophosphamide, TAPA-Pulsed Dendritic Cell Therapy and Imiquimod in Progressive and/or Refractory Solid Malignancies (clinicaltrials.gov) - P1/2; N=17; Active, not recruiting; Sponsor: Kiromic, Inc.; Trial completion date: Mar 2019 ➔ Mar 2020; Trial primary completion date: Mar 2019 ➔ Mar 2020

Clinical • Trial completion date • Trial primary completion date